Key facts
- Notable investors include Creative Destruction Lab, University of Toronto, University of Toronto Entrepreneurship, Transform Investments, Blueriver Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Arma Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Arma Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arma Biosciences
Developer of a sensor technology device platform designed for continuous monitoring of a multitude of physiological markers. The company's sensing tips with the device are compatible with saliva, blood, urine, sweat and tears and can be quickly developed to detect various health indications including cardiac biomarkers in the blood which are indicators of heart failure progression, including BNP, CRP and Cardiac Troponin, enabling people access to critical information of their health status from a physiological level.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2020
- Employees
- 8
- Website
- arma-bio.com/
- Ownership
- Privately Held (backing)
Arma Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arma Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arma Biosciences in its N-PORT filings yet. We sweep new filings monthly.